[go: up one dir, main page]

WO2009116764A3 - Inhibiteur de migration cellulaire, d'infiltration cellulaire ou de néovascularisation par dégradation de la fonction de la protéine ptk7 - Google Patents

Inhibiteur de migration cellulaire, d'infiltration cellulaire ou de néovascularisation par dégradation de la fonction de la protéine ptk7 Download PDF

Info

Publication number
WO2009116764A3
WO2009116764A3 PCT/KR2009/001298 KR2009001298W WO2009116764A3 WO 2009116764 A3 WO2009116764 A3 WO 2009116764A3 KR 2009001298 W KR2009001298 W KR 2009001298W WO 2009116764 A3 WO2009116764 A3 WO 2009116764A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell
degradation
function
inhibitor
cell migration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2009/001298
Other languages
English (en)
Korean (ko)
Other versions
WO2009116764A2 (fr
Inventor
이승택
권영근
신원식
맹용선
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Industry Academic Cooperation Foundation of Yonsei University
Original Assignee
Industry Academic Cooperation Foundation of Yonsei University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020090021595A external-priority patent/KR101123130B1/ko
Application filed by Industry Academic Cooperation Foundation of Yonsei University filed Critical Industry Academic Cooperation Foundation of Yonsei University
Priority to CN200980000012A priority Critical patent/CN101678075A/zh
Priority to JP2010503992A priority patent/JP2010522775A/ja
Publication of WO2009116764A2 publication Critical patent/WO2009116764A2/fr
Publication of WO2009116764A3 publication Critical patent/WO2009116764A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un inhibiteur de migration cellulaire, d'infiltration cellulaire ou de néovascularisation par dégradation d'une fonction de la protéine PTK7. Cet inhibiteur inhibe la néovascularisation, la migration cellulaire, l'infiltration cellulaire et l'adhérence cellulaire provoquées par VEGF et inhibe l'activation de PI3-kinase et Akt. Cet inhibiteur inhibe également l'activation de FAK et de la paxilline, ce qui permet d'inhiber efficacement la néovascularisation, la migration cellulaire et l'infiltration cellulaire dans un organisme vivant.
PCT/KR2009/001298 2008-03-17 2009-03-16 Inhibiteur de migration cellulaire, d'infiltration cellulaire ou de néovascularisation par dégradation de la fonction de la protéine ptk7 Ceased WO2009116764A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN200980000012A CN101678075A (zh) 2008-03-17 2009-03-16 通过阻断ptk7蛋白功能的细胞迁移、侵袭或血管发生的抑制剂
JP2010503992A JP2010522775A (ja) 2008-03-17 2009-03-16 Ｐｔｋ７タンパク質の機能阻害を通じる細胞の移動、浸潤または血管新生抑制剤

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20080024599 2008-03-17
KR10-2008-0024599 2008-03-17
KR1020090021595A KR101123130B1 (ko) 2008-03-17 2009-03-13 Ｐｔｋ７ 단백질의 기능 저해를 통한 세포의 이동, 침윤 또는 혈관신생 억제제
KR10-2009-0021595 2009-03-13

Publications (2)

Publication Number Publication Date
WO2009116764A2 WO2009116764A2 (fr) 2009-09-24
WO2009116764A3 true WO2009116764A3 (fr) 2009-11-26

Family

ID=41091371

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/001298 Ceased WO2009116764A2 (fr) 2008-03-17 2009-03-16 Inhibiteur de migration cellulaire, d'infiltration cellulaire ou de néovascularisation par dégradation de la fonction de la protéine ptk7

Country Status (1)

Country Link
WO (1) WO2009116764A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2380909A1 (fr) * 2010-04-26 2011-10-26 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Protéine PTK-7 impliquée dans le cancer du sein
NZ725480A (en) 2014-04-30 2024-08-30 Pfizer Anti-ptk7 antibody-drug conjugates

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007067730A2 (fr) * 2005-12-08 2007-06-14 Medarex, Inc. Anticorps monoclonaux humains contre la proteine tyrosine kinase 7 (ptk7) et procedes pour utiliser des anticorps anti-ptk7

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007067730A2 (fr) * 2005-12-08 2007-06-14 Medarex, Inc. Anticorps monoclonaux humains contre la proteine tyrosine kinase 7 (ptk7) et procedes pour utiliser des anticorps anti-ptk7

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Korean Society for Biochemistry and Molecular Biology, Spring Conference", 2005, article SHIN, W. S. ET AL.: "Extracellular domain of PTK7 inhibits the VEGF-induced migration, invasion and tube formation of HUVECs", pages: 293 *
"Korean Society for Biochemistry and Molecular Biology, Spring Conference", 2007, article SHIN, W. S. ET AL.: "The extracellular domain of PTK7 prevents the VEGF-induced movement of HUVECs through reducing actin polymerization", pages: 319 *

Also Published As

Publication number Publication date
WO2009116764A2 (fr) 2009-09-24

Similar Documents

Publication Publication Date Title
WO2007142752A3 (fr) Dispositifs médicaux implantables composites en biocéramique-polymère
WO2010060937A3 (fr) Combinaisons inhibitrices hsp90
WO2010136492A3 (fr) Protéines de liaison à l'antigène
WO2009129246A3 (fr) Compositions et leurs procédés de préparation et d'utilisation
WO2010045388A3 (fr) Utilisation des protéines de liaison aux mmp-9 et mmp-12 dans le traitement et la prévention de la sclérose systémique
WO2011037978A3 (fr) Conducteur de cadençage de type fil de guidage
EP4303236A3 (fr) Agent thérapeutique inducteur de cytotoxicité
WO2007143674A3 (fr) Procédés pour des posologies buccales, linguales ou sublinguales d'epinéphrine pour le traitement d'urgences allergiques
IL211930A (en) Peptides and nonsense for their use in preventing cell adhesion
BRPI0914017A2 (pt) composição adesiva, método de aderência e corpo ligado aderido
EP2246402A4 (fr) Composition de résine, stratifié l'utilisant et corps moulé utilisant le stratifié
WO2010132370A8 (fr) Peptides solubles de la famille trem-1 et procédés d'utilisation
WO2009142738A3 (fr) Compositions et procédés utilisables en matière de diagnostic et de traitement du cancer
WO2009106831A3 (fr) Composition pharmaceutique
MX2009004186A (es) Derivados de 2-fenil-6-aminocarbonil-pirimidina.
WO2009156182A3 (fr) Dérivés de l'uracile et leur utilisation
WO2009068708A3 (fr) Composition pharmaceutique à libération prolongée de somatostatine ou d'un analogue de celle-ci
WO2009103959A3 (fr) Médicament
WO2008154132A3 (fr) Dispositifs médicaux implantables ayant des revêtements de copolymère bloc élastomère
ZA201000581B (en) 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamide and 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]-diazepine-7-carboxamide derivatives,preparation and therapeutic use thereof
WO2009156071A8 (fr) Combinaison de dérivés d'amidine avec des depsipeptides cycliques
WO2009116764A3 (fr) Inhibiteur de migration cellulaire, d'infiltration cellulaire ou de néovascularisation par dégradation de la fonction de la protéine ptk7
WO2009123486A8 (fr) Utilisation de composés pour le traitement de cytotoxicités induites par la protéine tau
WO2010097501A3 (fr) Traitement combiné
WO2009108340A3 (fr) Agoniste de la leptine et méthodes d’utilisation

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980000012.1

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2010503992

Country of ref document: JP

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09722326

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09722326

Country of ref document: EP

Kind code of ref document: A2